Technology IP & products

Technology IP & products


Our technology & IP

  • The technology is based on the pharmaceutical modulation (not DDS) of existing and proven CNS drugs to generate a new efficacy/safety profile, enabling new IP, new indications, and premium pricing. This technology is versatile and adaptable to numerous classes of CNS drugs and indications.
  • Our approach benefits from rapid and lower cost development programs, enabling an accelerated time to market.
  • Our use of safety proven registered molecules ensures a low risk of late stage project failure.
  • Our technology and products are covered by a robust portfolio of patents

 

Our products

  • Theranexus’ products are fixed dose combinations between established and proven CNS drugs and off-patent, FDA/EMA registered and safety proven molecules.
  • Theranexus’ first product, THN102, composed of modafinil and THN02, is positioned to treat the residual sleepiness in narcoleptic patients (50% to 70% of narcoleptic patients). This is a first-in-class candidate combination, with a completed regulatory non-clinical phase and a proven safety in healthy subjects. It is currently under investigation in a clinical proof of concept in narcoleptic patients.